GH
Guardant Health, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$179.38
−2.03%Next report
Analyst consensus
- Next report date
- Oct 28, 2026
- EPS estimate
- -$0.29
- Revenue estimate
- $350.8M
Latest reported
- Last report date
- Jul 30, 2026
- EPS actual
- -$0.90
- EPS estimate
- -$0.76
- Revenue actual
- $335.0M
- Revenue estimate
- $314.2M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -24.8%
- Revenue beats (12Q)
- 8
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $199
- PT range
- $180 – $225
- Analysts
- 18
18 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Jul 30, 2026 | -$0.76 | -$0.90 | Miss -18.14% | $335.0M |
| May 7, 2026 | -$0.47 | -$0.85 | Miss -80.85% | $301.7M |
| Feb 19, 2026 | -$0.42 | -$0.50 | Miss -19.05% | $281.3M |
| Oct 29, 2025 | -$0.48 | -$0.39 | Beat 18.75% | $265.2M |
| Jul 30, 2025 | -$0.52 | -$0.44 | Beat 15.38% | $232.1M |
| Apr 30, 2025 | -$0.61 | -$0.49 | Beat 19.67% | $203.5M |
| Feb 20, 2025 | -$0.75 | -$0.62 | Beat 17.33% | $201.8M |
| May 9, 2024 | -$0.72 | -$0.46 | Beat 36.11% | $168.5M |
| Feb 22, 2024 | -$0.93 | -$1.58 | Miss -69.89% | $155.1M |
| Aug 3, 2023 | -$1.25 | -$0.67 | Beat 46.40% | $137.2M |
| Feb 23, 2023 | -$1.40 | -$1.36 | Beat 2.86% | $126.9M |
| Nov 3, 2022 | -$1.27 | -$1.58 | Miss -24.41% | $117.4M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 28, 2026